SHIPPEO
4.3.2020 11:12:12 CET | Business Wire | Press release
Samy Kchok brings over 20 years of Supply Chain expertise to Shippeo, the European leader in Supply Chain visibility.
Following a €20 million fundraising announcement in February 2020, Shippeo is appointing Samy Kchok as Sales Director France to strengthen its team and accelerate its growth in France. Thanks to his 22 years working with the largest French retailers (E.Leclerc, Carrefour, Monoprix), Samy Kchok will leverage his Supply Chain expertise and solid knowledge of shippers' challenges to continue Shippeo's significant development in France.
Samy Kchok will be working alongside Lucien Besse in Paris, leading the sales and pre-sales teams to further develop Shippeo’s client base on the French market. He will also be in charge of supporting the ambitious recruitment plan announced following the recent fundraising campaign.
"We are thrilled to welcome Samy to our team. We have been following him for several years now. He has the dual capacity of deeply understanding our offer and the expectations of executives in terms of Supply Chain. His expertise will undoubtedly be a great asset to complete our leadership position in Europe ." Explains Lucien Besse, CEO and co-founder of Shippeo.
Samy Kchok adds: "I’m truly excited to join Shippeo. It's an innovative company that I've seen grow from a shipper’s point of view. My experience in the retail sector has made me particularly conscious of the expectations in the field and the new challenges arising in the Supply Chain. I am looking forward to applying these skills to further develop the market’s leading solution ".
Biography
Samy Kchok (44) began his career at E.Leclerc, in the Sales Administration (Scamark) and Logistics (Logilec) departments. In 2002 he joined Carrefour Group as a Transport Buyer, before moving on to become Supply Chain and Procurement Manager, Upstream Transport Director, Transport Projects Director and then Supply Transformation Programme Director. In 2018, he joined Monoprix / Samada as Logistics and Transport Organization Director. Samy Kchok is a graduate of l’École Supérieure des Transports de Paris and holds a DESS degree in Transport and Logistics from Paris-Sorbonne University.
Learn more about Shippeo, the European leader in supply chain visibility: www.shippeo.com
https://www.shippeo.com/press-releases/samy-kchok-appointed-sales-director-france-shippeo
View source version on businesswire.com: https://www.businesswire.com/news/home/20200304005306/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom